Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07318597 | Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) | PHASE2 | RECRUITING | 99 | — | — | May 6, 2026 | Sep 17, 2028 | May 29, 2026 | 6 | United States, Latvia +2 |
| Arm | Type | Description |
|---|---|---|
| DBTP-Arm1 | EXPERIMENTAL | - |
| DBTP-Arm2 | EXPERIMENTAL | - |
| DBTP-Arm3 | PLACEBO_COMPARATOR | - |
| OLE-Arm1 | EXPERIMENTAL | - |
| OLE-Arm2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN13335 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Documented clinical diagnosis of PAH (Group 1 PH according to the 7th World Symposium on Pulmonary Hypertension (WSPH)) 2. WHO functional class II or III (slight to marked limitation of functional status due to PAH) 3. Receiving background Standard Of Care (SOC) therapy f...